The Current Gap
Acute Myeloid Leukemia (AML) remains a challenging disease with poor long-term outcomes despite significant advancements in treatment.
While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival remain elusive, particularly for older or unfit patients who cannot tolerate intensive chemotherapy or stem cell transplants ...
Our Breakthrough approach
Cycuria Therapeutics is revolutionizing blood cancer treatment with its proprietary engineered cytokines.
Our approach directly and specifically targets leukemic cells and their progenitor stem cells, while preserving healthy blood formation and minimizing systemic toxicity...
High incidence rate for AML,
specially in >60 yrs population
in every 100.000
Poor Overall survival rate
for AML patients
3-year survival rate
TEAM
Our experienced management team brings deep expertise in cytokine biology, protein engineering, clinical hemato-oncology and early-stage drug discovery and development
Prof. Dr. Philipp J. Jost
Inventor, Co-Founder & CSO
Dr. Nisit Khandelwal
Co-Founder & CEO
Prof. Dr. Felix Wieland
Directorem. Uni Heidelberg (BZH)
Prof. Dr. Walter Nickel
Managing DirectorofBZH, Uni Heidelberg
Our Blog
Latest CYCURIA News
Cycuria to Present at the Upcoming Biotech Summit Austria
Date: 9-11th October, 2024 Join our CEO as he presents the Cycuria story at the upcoming Biotech Summit Austria in Innsbruck.
RIPK3 Restricts Myeloid Leukemogenesis
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death andDifferentiation of Leukemia Initiating Cells. Cancer Cell. 2016
XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009
XIAP discriminates between type I and type II FAS-inducedapoptosis. Nature 2009
Contact Us
Cycuria Therapeutics GmbH
Center for Knowledge Transfer II (ZWT II)
Medical Science City Graz
Stiftingtalstraße 14
8010 Graz
Austria